AU2020102693A4 - Modulated milk powder with IgG, α-lactalbumin and lactoferrin and preparation method thereof - Google Patents
Modulated milk powder with IgG, α-lactalbumin and lactoferrin and preparation method thereof Download PDFInfo
- Publication number
- AU2020102693A4 AU2020102693A4 AU2020102693A AU2020102693A AU2020102693A4 AU 2020102693 A4 AU2020102693 A4 AU 2020102693A4 AU 2020102693 A AU2020102693 A AU 2020102693A AU 2020102693 A AU2020102693 A AU 2020102693A AU 2020102693 A4 AU2020102693 A4 AU 2020102693A4
- Authority
- AU
- Australia
- Prior art keywords
- powder
- whey protein
- parts
- mixed powder
- lactalbumin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000843 powder Substances 0.000 title claims abstract description 128
- 108010063045 Lactoferrin Proteins 0.000 title claims abstract description 58
- 102000010445 Lactoferrin Human genes 0.000 title claims abstract description 58
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 title claims abstract description 58
- 235000021242 lactoferrin Nutrition 0.000 title claims abstract description 58
- 229940078795 lactoferrin Drugs 0.000 title claims abstract description 58
- 210000004080 milk Anatomy 0.000 title claims abstract description 29
- 235000013336 milk Nutrition 0.000 title claims abstract description 28
- 239000008267 milk Substances 0.000 title claims abstract description 28
- 102000004407 Lactalbumin Human genes 0.000 title claims description 11
- 108090000942 Lactalbumin Proteins 0.000 title claims description 11
- 235000021241 α-lactalbumin Nutrition 0.000 title claims description 11
- 238000002360 preparation method Methods 0.000 title abstract description 14
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 124
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 124
- 235000021119 whey protein Nutrition 0.000 claims abstract description 108
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 24
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 22
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 17
- 239000008101 lactose Substances 0.000 claims abstract description 17
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims abstract description 13
- 239000000203 mixture Substances 0.000 claims abstract description 13
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims abstract description 13
- 229960003080 taurine Drugs 0.000 claims abstract description 12
- 239000002211 L-ascorbic acid Substances 0.000 claims abstract description 11
- 235000000069 L-ascorbic acid Nutrition 0.000 claims abstract description 11
- 229960005070 ascorbic acid Drugs 0.000 claims abstract description 11
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims abstract description 11
- 229960001031 glucose Drugs 0.000 claims abstract description 11
- 235000008939 whole milk Nutrition 0.000 claims abstract description 11
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims abstract description 7
- 239000002994 raw material Substances 0.000 claims abstract description 6
- 239000011812 mixed powder Substances 0.000 claims description 85
- 238000000034 method Methods 0.000 claims description 23
- 238000000227 grinding Methods 0.000 claims description 10
- 239000008187 granular material Substances 0.000 claims description 5
- 238000005469 granulation Methods 0.000 claims description 5
- 229960001375 lactose Drugs 0.000 claims description 5
- 238000012216 screening Methods 0.000 claims description 5
- 230000007613 environmental effect Effects 0.000 claims description 2
- 102000009027 Albumins Human genes 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 abstract description 8
- 102000004169 proteins and genes Human genes 0.000 abstract description 8
- 108090000623 proteins and genes Proteins 0.000 abstract description 8
- 239000002245 particle Substances 0.000 abstract description 7
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 230000002776 aggregation Effects 0.000 abstract description 3
- 238000004090 dissolution Methods 0.000 abstract description 3
- 238000004220 aggregation Methods 0.000 abstract description 2
- 235000012041 food component Nutrition 0.000 abstract 1
- 239000012460 protein solution Substances 0.000 description 20
- 238000000108 ultra-filtration Methods 0.000 description 20
- 239000005862 Whey Substances 0.000 description 16
- 239000012528 membrane Substances 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 238000003756 stirring Methods 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 230000001954 sterilising effect Effects 0.000 description 12
- 238000004659 sterilization and disinfection Methods 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 9
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 8
- 241000283690 Bos taurus Species 0.000 description 8
- 210000003022 colostrum Anatomy 0.000 description 8
- 235000021277 colostrum Nutrition 0.000 description 8
- 239000012141 concentrate Substances 0.000 description 8
- 230000008014 freezing Effects 0.000 description 8
- 238000007710 freezing Methods 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 210000004379 membrane Anatomy 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 239000004627 regenerated cellulose Substances 0.000 description 8
- 229940014800 succinic anhydride Drugs 0.000 description 8
- 210000003743 erythrocyte Anatomy 0.000 description 7
- 235000016709 nutrition Nutrition 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 238000002076 thermal analysis method Methods 0.000 description 7
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 235000015097 nutrients Nutrition 0.000 description 6
- 229960002275 pentobarbital sodium Drugs 0.000 description 6
- 230000004620 sleep latency Effects 0.000 description 6
- 230000004622 sleep time Effects 0.000 description 6
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 5
- DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 5
- 241000287828 Gallus gallus Species 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 230000035322 succinylation Effects 0.000 description 5
- 238000010613 succinylation reaction Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 4
- 108010006464 Hemolysin Proteins Proteins 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 210000000628 antibody-producing cell Anatomy 0.000 description 4
- 239000001110 calcium chloride Substances 0.000 description 4
- 229910001628 calcium chloride Inorganic materials 0.000 description 4
- 235000011148 calcium chloride Nutrition 0.000 description 4
- 235000013365 dairy product Nutrition 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 231100000025 genetic toxicology Toxicity 0.000 description 4
- 239000003228 hemolysin Substances 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 206010057249 Phagocytosis Diseases 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 229960000796 barbital sodium Drugs 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 235000012631 food intake Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 235000020256 human milk Nutrition 0.000 description 3
- 210000004251 human milk Anatomy 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000008782 phagocytosis Effects 0.000 description 3
- 230000007958 sleep Effects 0.000 description 3
- RGHFKWPGWBFQLN-UHFFFAOYSA-M sodium;5,5-diethylpyrimidin-3-ide-2,4,6-trione Chemical compound [Na+].CCC1(CC)C([O-])=NC(=O)NC1=O RGHFKWPGWBFQLN-UHFFFAOYSA-M 0.000 description 3
- 238000010953 Ames test Methods 0.000 description 2
- 231100000039 Ames test Toxicity 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 2
- 102000001490 Opioid Peptides Human genes 0.000 description 2
- 108010093625 Opioid Peptides Proteins 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000007674 genetic toxicity Effects 0.000 description 2
- 230000001738 genotoxic effect Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 230000003832 immune regulation Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000003399 opiate peptide Substances 0.000 description 2
- 210000003024 peritoneal macrophage Anatomy 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 101800000068 Antioxidant peptide Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000008133 Iron-Binding Proteins Human genes 0.000 description 1
- 108010035210 Iron-Binding Proteins Proteins 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229960002319 barbital Drugs 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000013350 formula milk Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000006180 nutrition needs Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- RLZZZVKAURTHCP-UHFFFAOYSA-N phenanthrene-3,4-diol Chemical compound C1=CC=C2C3=C(O)C(O)=CC=C3C=CC2=C1 RLZZZVKAURTHCP-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 231100000527 sperm abnormality Toxicity 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000003390 teratogenic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000009602 toxicology test Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C21/00—Whey; Whey preparations
- A23C21/06—Mixtures of whey with milk products or milk components
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/15—Reconstituted or recombined milk products containing neither non-milk fat nor non-milk proteins
- A23C9/1512—Reconstituted or recombined milk products containing neither non-milk fat nor non-milk proteins containing isolated milk or whey proteins, caseinates or cheese; Enrichment of milk products with milk proteins in isolated or concentrated form, e.g. ultrafiltration retentate
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/16—Agglomerating or granulating milk powder; Making instant milk powder; Products obtained thereby
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Dairy Products (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The present invention relates to a modulated milk powder containing IgG,
a-lactalbumin and lactoferrin and a preparation method thereof. The modulated milk
powder containing IgG, a-lactalbumin and lactoferrin is prepared from the following
raw materials in parts by mass : 383~408 parts of whey protein powder containing
IgG, 37~42 parts of whey protein powder containing lactoferrin, 122~134 parts of
whey protein powder containing a-lactalbumin, 187~204 parts of anhydrous glucose
servings, 164~176 parts of whole milk powder, 48~52 parts of stachyose, 3.4~4.8
parts of isomerized lactose, 0.7~0.9 parts of L-ascorbic acid, 0.1~0.3 parts of taurine.
The present invention allows the isomerized lactose and stachyose particles and the
whey protein powder particles to be physically combined without changing the
nutritional components and biochemical composition to prevent the aggregation of
whey protein particles and prevent the whey protein powder combine with other
protein powders to improve the powder's flowability, solubility, dissolution speed,
production efficiency, and mouth feel when it is took with dry state.
1
Description
Modulated milk powder with IgG, a-lactalbumin and lactoferrin and
preparation method thereof
The invention relates to a modulated milk powder containing IgG,
a-lactalbumin and lactoferrin and a preparation method thereof and
belongs to the technical field of dairy processing.
Childhood is the most important stage of life development. The
physiological, psychological, and pathological characteristics of age
groups are different from each other and are more distinct from adults.
The most significant physiological feature is the increase in the amount of
the body and organs; the perfect differentiation of cells, tissues and
organs and the maturity of their functions.
Children need to obtain nutrients from food to repair old tissues,
grow new tissues, generate energy, and maintain physiological activities.
The younger the age, the faster the growth, the stronger the metabolism,
but the less developed the digestive function. How to choose foods and
feeding methods that meet the nutritional needs of children of different
ages is an important issue in children's health care.
Children's requirements for various nutrients are different from
adults, and there are also differences between age groups. Children's
modified milk powder is a nutritional supplement food that is currently
accepted and loved by children and parents. It is not only delicious, but
also can provide more comprehensive nutrition for children.
Lactoferrin is often only added as a nutrient-enhancing component
to enhance the grade of the product. However, lactoferrin is more
sensitive to heat, has poor thermal stability, and has strict environmental
pH requirements. Which not only leads to higher production cost and
waste of resources, but also may affect the effective use of other
components in formula milk powder, and ultimately affect the full use of
the immune function of the modulated milk powder containing it.
Whey protein is protein residues in the supernatant after casein
precipitation and separation. Whey protein is mainly composed of
p-lactoglobulin (55-60%) and a-lactalbumin (15-20%), bovine serum albumin (11%), immunoglobulin (9%), and a small amount of other
components such as lactoferrin, lipoprotein, biologically active factors
and enzymes (lacoperoxidase). Whey protein peptides have extremely
high nutritional value and physiological health functions. They play an
significant role in promoting the growth, development and disease
prevention of the body. They can be used as functional foods or food
additives and even medicines in people's daily lives. At present, various peptides have been found in whey protein, among which the types of active peptides mainly include opioid peptides, antihypertensive peptides, antioxidant peptides, antibacterial peptides and immunomodulatory peptides. Exogenous opioid peptides can stimulate the secretion of insulin and somatostatin in the digestive tract, regulate animal behavior, promote the intestinal absorption of water and electrolytes, regulate digestive tract movement, stimulate food intake, inhibit breathing and adjust sleep patterns. The peptides produced by the degradation of whey protein play an essential role in the immune regulation of the body, which can stimulate the proliferation of mouse spleen cells, and the enzymatic hydrolysis products can significantly increase the secretion of y-interferon.
The nutritional value of liquid milk sold in the market cannot be
compared with breast milk. This is because breast milk is naturally rich in
immunologically active substances, such as immunoglobulins (including
IgA, IgG and IgM, etc.), lactoferrin, enzymes and types up to hundreds of
low-abundance proteins, these low-abundance proteins often have
bioactivities such as regulating immunity and promoting metabolism. IgG
and IgM are essential in the defense of the intestinal mucosa of infants.
IgG can bind to viruses to make pathogens or prevent them from adhering
to the mucosal surface (Robert-Guroff, 2000). When increasing the
nutritional value of milk products in the prior art, the usual method is to adjust the ratio of casein to whey protein and adjust the types of fatty acids. However, it is difficult to simulate breast milk at the protein level by using active proteins such as immunoglobulin and other important functions. The studies of Troost et al. (2001) and Jasion et al. (2015) showed that lactoferrin and immunoglobulin in milk can avoid the digestive effects of the stomach and intestines, and maintain the body's antibacterial, anti-inflammatory, and increase immunity.
In view of the above-mentioned technical problems in the prior art, the present invention provides a modulated milk powder containing IgG, a-lactalbumin and lactoferrin and a preparation method thereof, which has extremely high nutritional value and can meet the needs of children for basic nutrients. The purpose of the present invention is achieved through the following technical solutions: Modulated milk powder containing IgG, a-lactalbumin and lactoferrin, made from the following raw materials in parts by mass: 383~408 parts of whey protein isolate powder containing IgG, and whey protein isolate powder containing lactoferrin 37 ~42 parts, 122~134 parts of whey protein powder containing a-lactalbumin, 187~204 parts of anhydrous glucose, 164~176 parts of whole milk powder, 48~52 parts of stachyose, isomerized lactose 3.4~ 4.8 parts, 0.7~0.9 parts of L-ascorbic acid, 0.1~0.3 parts of taurine. The IgG-containing isolated whey protein powder contains 25% IgG by mass;
The lactoferrin-containing whey protein isolate powder contains % by mass of lactoferrin; The alpha-lactalbumin-containing whey protein powder contains % by mass of alpha-lactalbumin. The preparation method of the modulated milk powder containing IgG, a-lactalbumin and lactoferrin includes the following steps: S1. Feed anhydrous glucose, whole milk powder, stachyose, isomerized lactose, L-ascorbic acid, and taurine in proportions and mix them uniformly to form mixed powder A; S2, IgG-containing whey protein powder, lactoferrin-containing whey protein powder, a-lactalbumin-containing whey protein powder and mixed powder A with a mass of 25 to 42% are mixed uniformly, to obtain mixed powder B. The operating condition is that the relative humidity is 30~35% and the temperature is 20~23°C; S3. Re-granulate the remaining mixed powder A and mixed powder B. The method of re-granulation is that the mixed powder A and mixed powder B are fed into a single-shaft roller press and pressed to form a successfully combined mixed powder C. And uncombined mixed powder A and mixed powder B; S4. The output of step S3 enters the grinding device and the vibrating screening device. The grinding device grinds the mixed powder C containing blocky heterogeneity and homogenizes the mixed powder D into the finished product. The mixed powder A and B are sifted out and recycled into the single-shaft roller press again. Preferably, in step S3, the remaining mixed powder A and mixed powder B are fed through two powder inlets respectively, and the feeding speed of A is 1.4-2.3 times that of the mixed powder B. In step S3, the uniaxial roller press is equipped with a heat conduction device, the temperature is 30-35°C, the relative humidity is
-35%, and the manufacturing environment temperature is 20-25°C; The rotation speed of the rollers of the single-shaft roller press is 30-60 rpm. It also includes: S5, mixed powder D and then go back to the single-shaft roller press to re-press 2~3 times. Wherein, the method for preparing IgG-containing whey protein isolate powder includes the following steps: (1) Select the qualified bovine colostrum and add 1mol/L CaCl2 12~20ml/L, adjust the pH to 5.5~7.5, and stir in the water bath at ~55°C for 15~20min; (2) Degrease the bovine colostrum on a high-speed refrigerated centrifuge. The speed of the centrifuge is 8000~10000 rpm, the temperature is 2~5°C, and the centrifugation time is 12~20min;
(3) Using regenerated cellulose ultrafiltration membrane with a molecular weight cut-off of 5-20KDa for concentration, the operating conditions are temperature 25 °C , pressure 0.10~0.2MPa, flow rate ~35m/s, concentration multiplying factor to 5~10 times to get the first time Whey (4) Add deionized water to the first whey, the material-to-liquid ratio is 1:1~4:1, the flow rate is 25~40m/s, the pressure is 0.1~0.2MPa. The regenerated cellulose ultrafiltration membrane with molecular weight cut-off 5~20KDa is used in the second concentration, removing lactose, obtaining a purified whey protein concentrate; (5) The purified whey protein concentrate is concentrated by ultrafiltration, and then is eluted isocratically to obtain the final whey; for the ultrafiltration and concentration, first select a 40~60kDa membrane for ultrafiltration, and then use a 5~15kDa membrane to filter out liquid; (6) The final whey liquid is dried and frozen. For the first time, the freezing temperature is -30~-40°C, and the freezing time is 1.5~2.5h; then the second drying is sublimated, and the temperature is first cooled to and maintained at -35 ~ -40°C, vacuum again to make the vacuum reach ~50Pa, then heat and sublimate for 6~7 hours; (7) Finally, thermal analysis is conducted under vacuum conditions. The analysis temperature of the thermal analysis device is 35-45°C, the analysis time is 6.5-7.5h, and the moisture content is controlled to obtain IgG-containing isolated whey protein powder. Wherein, in the preparation method of lactoferrin-containing whey protein isolate powder, the lactoferrin and whey protein isolate powder are put into a mixer on the basis of the proportions for mixing, and the mixing time is 30 minutes, and then go through the microwave sterilization tunnel. The oven controls the sterilization temperature of ~50°C for tunnel sterilization. Wherein, the method for preparing whey protein powder containing a-lactalbumin is (1) Dissolve whey protein in water to prepare a 7.3% whey protein solution; add succinic anhydride to the whey protein solution for succinylation, and the added amount of succinic anhydride is 6.5-12.8% of the mass of the protein solution; Adjust the pH of the succinylated whey protein solution to 8; (3) Then carry out microwave treatment, said microwave power is 1000~1200W, microwave time is 30~60s; (4) Adjust the pH of the protein solution after microwave treatment to 4, stir for 30 minutes, centrifuge at 4000r/min for 20 minutes, and take the precipitated part; (5) Add a-lactalbumin into the precipitated part according to the proportion, stir evenly, and vacuum dry to obtain a-lactalbumin-containing whey protein powder. The modulated milk powder containing IgG, a-lactalbumin and lactoferrin provided by the present invention and the preparation method thereof have the following technical effects: Without changing the nutritional composition and biochemical composition, the isomerized lactose and stachyose particles and the whey protein powder particles are physically combined to prevent the aggregation of whey protein particles and prevent the whey protein powder from interacting with other proteins. The combined powder particles can improve the powder's fluidity, solubility, dissolution speed, production efficiency, and mouth feel. Lactoferrin is a very important non-heme iron-binding glycoprotein in milk. Lactoferrin not only participates in iron transport, but also has powerful biological functions such as broad-spectrum antibacterial, antioxidant, anti-cancer, and immune regulation. It is used in dairy products. Adding a certain amount of lactoferrin can increase the health function of dairy products while without altering the taste of dairy products. Microwave-assisted succinylation can increase the fluidity of whey protein powder from 1-4 to 4-7, increase the solubility, from 0.1g/ml to at least 0.5g/ml, increase the dissolution rate, improve taste and reduce powder choking in mouth and throat; Adding a proper amount of taurine and other ingredients can effectively promote the intellectual and physical development of young children.
The embodiments of the present invention are intended to be illustrative, and not to limit the scope of the present invention. Any slight difference in nutrient composition due to the difference in milk milk source should not be used as a reason for the inconsistency between the embodiment of the present invention and the specification, so the present invention aims to protect the purpose of adding nutrients, rather than to make the ratio particularly strict. The ground is limited to a specific value. Example 1 Modulated milk powder containing IgG, a-lactalbumin and lactoferrin is made from the following raw materials in parts by mass: 397 parts of whey protein isolate powder containing IgG, 41 parts of whey protein isolate powder containing lactoferrin, 132 parts of whey protein powder containing a-lactalbumin, 185 parts of anhydrous glucose, 168 parts of whole milk powder, 51 parts of stachyose, 3.6 parts of isomerized lactose, 0.7 points of L-ascorbic acid, 0.1 part of taurine
. The IgG-containing isolated whey protein powder contains 25% IgG by mass; The lactoferrin-containing whey protein isolate powder contains % by mass of lactoferrin; The alpha-lactalbumin-containing whey protein powder contains % by mass of alpha-lactalbumin. The preparation method of the modulated milk powder containing IgG, a-lactalbumin and lactoferrin includes the following steps: S1. Feed anhydrous glucose, whole milk powder, stachyose, isomerized lactose, L-ascorbic acid, and taurine in proportions and mix them uniformly to form mixed powder A; S2, IgG-containing whey protein isolate powder, lactoferrin-containing whey protein isolate powder, a-Lactalbumin-containing whey protein powder and 30% by mass mixed powder A are evenly mixed. The relative humidity is controlled to be -35%, and the temperature is 20 to 23°C. Mixed powder B is obtained. S3. Re-granulate the remaining mixed powder A and mixed powder
B. The method of re-granulation is that the mixed powder A and mixed powder B are fed into a single-shaft roller press and pressed to form a successfully combined mixed powder C. And uncombined mixed powder A and mixed powder B; S4. The output of step S3 enters the grinding device and the vibrating screening device. The grinding device grinds the mixed powder C containing blocky heterogeneity and homogenizes the mixed powder D into the finished product. The mixed powder A and B are sifted out and recycled into the single-shaft roller press again. Preferably, in step S3, the remaining mixed powder A and mixed powder B are fed through two powder inlets respectively, and feeding speed of powder A is 1.5 times that of the mixed powder B. In step S3, the uniaxial roller press is equipped with a heat conduction device, the temperature is 30-35°C, the relative humidity is -35%, and the external environment temperature of the uniaxial roller press is 20-25°C; The rotation speed of the rollers of the uniaxial roller press is 60 rpm. Wherein, the method for preparing IgG-containing whey protein isolate powder includes the following steps: (1) Select the qualified bovine colostrum and add 1 mol/L CaCl2 ml/L, adjust the pH to 5.5, and stir in a water bath at 55°C for 20 minutes; (2) Degrease the bovine colostrum on a high-speed refrigerated centrifuge. The speed of the centrifuge is 8000~10000 rpm, the temperature is 4°C, and the centrifugation time is 20min; (3) Use regenerated cellulose ultrafiltration membrane with a molecular weight cut-off of 15KDa for concentration. The operating conditions are temperature 25°C, pressure 0.2MPa, flow rate 35m/s, and concentration factor to 8 to obtain the first whey liquid;
(4) Add deionized water to the first whey, with a material-to-liquid ratio of 1:1, a flow rate of 25m/s, and a pressure of 0.2MPa. The regenerated cellulose ultrafiltration membrane with molecular weight cut-off of 15KDa for the second concentration, removing lactose and obtain purified whey protein concentrate; (5) Purified whey protein concentrate is concentrated by ultrafiltration, and then eluted isocratically to obtain the final whey; for the ultrafiltration and concentration, first select a 60kDa membrane for ultrafiltration, and then use a 15kDa membrane to filter the filtrate. (6) The final whey is dried and frozen at the freezing temperature -40°C, and the freezing time is 2.5h; then the second drying is at
temperature -40°C, and then vacuumed. Make the vacuum reach 50Pa,
then heat and sublimate for 6 hours; (7) Finally, thermal analysis is conducted under vacuum conditions. The analysis temperature of the thermal analysis device is 45°C, the analysis time is 6.5h, and the moisture content is controlled to obtain IgG-containing isolated whey protein powder. Wherein, in the preparation method of lactoferrin-containing whey protein isolate powder, the lactoferrin and whey protein isolate powder are put into a mixer according to the proportions for mixing, and the mixing time is 30 minutes, and the person moves through the microwave sterilization tunnel. The oven controls the sterilization temperature of °C to carry out tunnel sterilization. Wherein, the method for preparing whey protein powder containing a-lactalbumin is (1) Dissolve whey protein in water to prepare a 7.3% whey protein solution; add succinic anhydride to the whey protein solution for succinylation, and the added amount of succinic anhydride is 12.8% of the mass of the protein solution; Adjust the pH of the succinylated whey protein solution to 8; (3) Then carry out microwave treatment, said microwave power is 1000W, microwave time is 45s; (4) Adjust the pH of the protein solution after microwave treatment to 4, stir for 30 minutes, centrifuge at 4000r/min for 20 minutes, and take the precipitated part; (5) Add a-lactalbumin into the precipitated part according to the proportion, stir evenly, and vacuum dry to obtain a-lactalbumin-containing whey protein powder. Example 2 Modulated milk powder containing IgG, a-lactalbumin and lactoferrin, made from the following raw materials in parts by mass: 405 parts of whey protein isolate powder containing IgG, 38 parts of whey protein isolate powder containing lactoferrin, 125 parts of whey protein powder containing a-lactalbumin, 201 parts of anhydrous glucose, 170 parts of whole milk powder, 50 parts of stachyose, 4.5 parts of isomerized lactose, 0.7 points of L-ascorbic acid, 0.3 parts of taurine .
The IgG-containing isolated whey protein powder contains 25% IgG by mass; The lactoferrin-containing whey protein isolate powder contains % by mass of lactoferrin; The alpha-lactalbumin-containing whey protein powder contains % by mass of alpha-lactalbumin. The preparation method of the modulated milk powder containing IgG, a-lactalbumin and lactoferrin includes the following steps: S1. Feed anhydrous glucose, whole milk powder, stachyose, isomerized lactose, L-ascorbic acid, and taurine in proportions and mix them uniformly to form mixed powder A;
S2, IgG-containing whey protein isolate powder, lactoferrin-containing whey protein isolate powder, a-Lactalbumin-containing whey protein powder and the mixed powder A with a mass of 35% are mixed uniformly, the relative humidity of the mixed material is controlled to 35%, and the temperature is 20°C to obtain the mixed powder B. S3. Re-granulate the remaining mixed powder A and mixed powder B. The method of re-granulation is that the mixed powder A and mixed powder B are fed into a single-shaft roller press and pressed to form a successfully combined mixed powder C. And uncombined mixed powder A and mixed powder B; S4. The output of step S3 enters the grinding device and the vibrating screening device. The grinding device grinds the mixed powder C containing blocky heterogeneity and homogenizes the mixed powder D into the finished product. The mixed powder A and powder B are sifted out and recycled into the single-shaft roller press again. Preferably, in step S3, the remaining mixed powder A and mixed powder B are fed through two powder inlets respectively, and the powder output speed is 1.8 times that of the mixed powder B. In step S3, the uniaxial roller press is equipped with a heat conduction device, the temperature is 30-35°C, the humidity in the uniaxial roller press is 30-35%, and the external environment temperature of the uniaxial roller press is 20-25°C; The rotation speed of the rollers of the single-shaft roller press is 30-60 rpm. It also includes: S5, mixed powder D and then go back to the single-shaft roller press to re-press 2~3 times. Wherein, the method for preparing IgG-containing whey protein isolate powder includes the following steps: (1) Select the qualified bovine colostrum, add 1 mol/L CaCl2
16ml/L, adjust the pH to 7, and stir in a water bath at 45°C for 15 minutes; (2) Degrease the bovine colostrum on a high-speed refrigerated centrifuge at a speed of 10,000 rpm, a temperature of 2°C, and a centrifugal time of 20 minutes; (3) Use regenerated cellulose ultrafiltration membrane with a molecular weight cut-off of 20KDa for concentration. The operating conditions are temperature 25°C, pressure 0.2MPa, flow rate 35m/s, and concentration multiple to 5 times to obtain the first whey liquid; (4) Add deionized water to the first whey, with a material-to-liquid ratio of 2:1, a flow rate of 30m/s, and a pressure of 0.2MPa. The regenerated cellulose ultrafiltration membrane with molecular weight cut-off 1OKDa is used in the second concentration, removing lactose, to obtain a purified whey protein concentrate; (5) Purified whey protein concentrate is concentrated by ultrafiltration, and then eluted isocratically to obtain the final whey; for the ultrafiltration and concentration, first select a 50kDa membrane for ultrafiltration, and then use a 10kDa membrane to filter the filtrate; (6) The final whey is dried and frozen at freezing temperature is -30°C, and the freezing time is 1.5h; then the second drying temperature
is at -40°C, and the go through vacuum at 40Pa, followed by heat and sublimate for 6 hours; (7) Finally, thermal analysis is conducted under vacuum conditions. The analysis temperature of the thermal analysis device is 45°C, the analysis time is 7.5h, and the moisture content is controlled to obtain the separated whey protein powder containing IgG. Wherein, in the preparation method of lactoferrin-containing whey protein isolate powder, the lactoferrin and whey protein isolate powder are put into a mixer according to the proportions for mixing, and the mixing time is 30 minutes, and the person moves through the microwave sterilization tunnel. The oven controls the sterilization temperature to °C for tunnel sterilization. Wherein, the method for preparing whey protein powder containing a-lactalbumin is (1) Dissolve whey protein in water to prepare a 7.3% whey protein solution; add succinic anhydride to the whey protein solution for succinylation, and the added amount of succinic anhydride is 12.5% of the mass of the protein solution; Adjust the pH of the succinylated whey protein solution to 8; (3) Then carry out microwave treatment, said microwave power is 1200W, microwave time is 60s; (4) Adjust the pH of the protein solution after microwave treatment to 4, stir for 30 minutes, centrifuge at 4000r/min for 20 minutes, and take the precipitated part; (5) Add a-lactalbumin into the precipitated part according to the proportion, stir evenly, and vacuum dry to obtain a-lactalbumin-containing whey protein powder. Example 3 Modulated milk powder containing IgG, a-lactalbumin and lactoferrin, made from the following raw materials in parts by mass: 397 parts of whey protein isolate powder containing IgG, 40 parts of whey protein isolate powder containing lactoferrin, 130 parts of whey protein powder containing a-lactalbumin, 196 parts of anhydrous glucose, 175 parts of whole milk powder, 50 parts of stachyose, 4.2 parts of isomerized lactose, 0.8 parts of L-ascorbic acid, 0.2 parts of taurine .
The IgG-containing isolated whey protein powder contains 25% IgG by mass;
The lactoferrin-containing whey protein isolate powder contains % by mass of lactoferrin; The alpha-lactalbumin-containing whey protein powder contains % by mass of alpha-lactalbumin. The preparation method of the modulated milk powder containing IgG, a-lactalbumin and lactoferrin includes the following steps: S1. Feed anhydrous glucose, whole milk powder, stachyose, isomerized lactose, L-ascorbic acid, and taurine in proportions and mix them uniformly to form mixed powder A; S2. IgG-containing whey protein isolate powder, lactoferrin-containing whey protein isolate powder, a-Lactalbumin-containing the whey protein powder and the mixed powder A with a mass of 40% are mixed uniformly, the relative humidity of the mixed material is controlled to 35%, and the temperature is 23°C to obtain the mixed powder B. S3. Re-granulate the remaining mixed powder A and mixed powder B. The method of re-granulation is that the mixed powder A and mixed powder B are fed into a single-shaft roller press and pressed to form a successfully combined mixed powder C. And uncombined mixed powder A and mixed powder B; S4. The output of step S3 enters the grinding device and the vibrating screening device. The grinding device grinds the mixed powder C containing blocky heterogeneity and homogenizes the mixed powder D into the finished product. The mixed powder A and powder B are sifted out and recycled into the single-shaft roller press again. Preferably, in step S3, the remaining mixed powder A and mixed powder B are fed through two powder inlets respectively, and the powder A output speed is twice that of the mixed powder B. In step S3, the uniaxial roller press is equipped with a heat conduction device, the temperature is 30°C, the internal humidity of the uniaxial roller press is 35%, and the external environment temperature of the uniaxial roller press is 20°C; The rotation speed of the roller is 50 rpm. It also includes: S5, mixed powder D and then go back to the single-shaft roller press to re-press 53 times. Wherein, the method for preparing IgG-containing whey protein isolate powder includes the following steps: (1) Select the qualified bovine colostrum, add 1 mol/L CaCl2 17 ml/L, adjust the pH to 5.5, and stir in a water bath at 35°C for 20 minutes; (2) Degrease the bovine colostrum on a high-speed refrigerated centrifuge. The speed of the centrifuge is 10,000 rpm, the temperature is 2.5 0C, and the centrifugation time is 20 minutes; (3) Use regenerated cellulose ultrafiltration membrane with a molecular weight cut-off of 20KDa for concentration. The operating conditions are temperature 25 0 C, pressure 0.1OMPa, flow rate 35m/s, and concentration factor to 10 times to obtain the first whey liquid; (4) Add deionized water to the first whey, with a material-to-liquid ratio of 3:1, a flow rate of 40m/s, and a pressure of 0.2MPa. The regenerated cellulose ultrafiltration membrane that retain molecular weight 20KDa for the second concentration, remove lactose, obtain purified whey protein concentrate; (5) The purified whey protein concentrate is concentrated by ultrafiltration, and then is eluted isocratically to obtain the final whey; for the ultrafiltration and concentration, first select a 50kDa membrane for ultrafiltration, and then use a 5kDa membrane to filter the filtrate; (6) The final whey is dried and frozen at the freezing temperature -30°C, and the freezing time is 1.5h; then the second drying is sublimated, and the temperature is first cooled to and maintained between -40°C, and go through vacuum at 50Pa, followed by heat and sublimate for 6 hours; (7) Finally, thermal analysis is carried out under vacuum conditions. The analysis temperature is 35°C, the analysis time is 7.5h, and the moisture content is controlled to obtain IgG-containing isolated whey protein powder. Wherein, in the preparation method of lactoferrin-containing whey protein isolate powder, the lactoferrin and whey protein isolate powder are put into a mixer according to the proportions for mixing, and the mixing time is 30 minutes, and then go through the microwave sterilization tunnel. The oven controls the sterilization temperature of ~50°C for tunnel sterilization. Wherein, the method for preparing whey protein powder containing a-lactalbumin is (1) Dissolve whey protein in water to prepare a 7.3% whey protein solution; add succinic anhydride to the whey protein solution for succinylation, and the added amount of succinic anhydride is 8.5% of the mass of the protein solution. Adjust the pH of the succinylated whey protein solution to 8; (3) Then carry out microwave treatment, said microwave power is 1000W, microwave time is 60s; (4) Adjust the pH of the protein solution after microwave treatment to 4, stir for 30 minutes, centrifuge at 4000r/min for 20 minutes, and take the precipitated part; (5) Add a-lactalbumin into the precipitated part according to the proportion, stir evenly, and vacuum dry to obtain whey protein powder. Product quality inspection analysis: 1. The nutrient composition analysis of the product obtained in the above example is shown in Table 1:
Table 1 Nutritional ingredients project unit index Example Example Example 1 2 3 energy kJ/100g 1439-2157 1975 1862 1942 protein g/100g 24.4 32.4 34.8 32.7
fat g/100g 117.4 12.4 11.5 13.3
Carbohydrat g/100g >35.1 39.4 38.5 36.2 es sodium mg/100g 354 213 205 217
calcium mg/100g > 776 882 843 841
Lactoferrin mg/100g >80.0 121.5 126.4 124.5
IgG mg/100g 800 1027 1134 1038
a-lactalbumi mg/100g > 320 387 346 362 n Moisture % 5 3.4 3.2 3.7
2. The sensory indicators of the products obtained in the above
examples are shown in Table 2:
Table 2 Product sensory indicators project Claim Testing method test result Example Example Example 1 2 3 Color A uniform Take an appropriate qualified qualified qualified creamy yellow amount of the sample and Tissue Dry, uniform place it in a 50mL qualified qualified qualified morphol powder, no transparent container.
ogy or foreign objects Observe the color and traits visible to the texture under natural light, naked eye smell the smell, rinse your Taste or Has a pure milk mouth with warm water, qualified qualified qualified smell fragrance and taste the taste. Dissolva After stirring, it Take 11g sample and brew qualified qualified qualified bility can be quickly with 100ml of warm water dissolved in at 50-55°C to observe the water without solubility agglomeration
3. Immunity enhancement test
Samples: Take the samples prepared in Examples 1 to 3 as the sample
group, use the same amount of skimmed milk powder as the control
group in accordance with the examples.
Experimental animals: 60 mice with a mass of about 18-22g, both
male and female, were randomly divided into 5 groups, and each group
was randomly divided into 4 groups for testing.
Test method: According to the food intake of the test mice, the
maximum dose is designed to be lOg/d, directly fed for 30 days.
Immunity enhancement function evaluation method: Mouse spleen
lymphocyte transformation experiment induced by ConA: MTT method;
serum hemolysin determination: hemagglutination method;
antibody-producing cell detection: Jerne modified slide method; mouse
peritoneal macrophages phagocytic chicken red blood cell experiment:
semi-in vivo method.
The effect of the sample group on the anti-volume of mouse serum hemolysin is shown in Table 3:
Table 3 The effect of sample group on the anti-volume of serum
hemolysin in mice
project Number of Optical density animals difference (X s) (only)
Control group 5 189.24+10.35
Example 5 214.12+11.42
Example2 5 217.03+10.47
Example3 5 215.07+10.53
It can be seen from Table 1 that the sample group has a significant
difference in anti-volume number compared with the control group mice
(P<0.05).
The effect of the sample group on mouse antibody-producing cells is
shown in Table 4:
Table 4 Effects of samples on mouse antibody-producing cells
project Number of Number of antibody animals (only) producing cells/106(X s)
Control group 5 210.47+52.39
Example 5 335.42+42.37
Example2 5 354.16+45.34
Example3 5 347.27±43.76 It can be seen from Table 2 that the number of antibody-producing
cells in the sample group and the control group mice is significantly
different (P<0.01).
The effect of the sample group on the ability of mouse peritoneal
macrophages and chicken red blood cells is shown in Table 5:
Table 5 Effect of sample group on the ability of mouse peritoneal
macrophages to phagocytize chicken red blood cells
project Number of animals Phagocytosis (only) percentage/%(X s)
Control group 5 28.34+3.64
Example 5 36.41+2.57
Example2 5 35.18+3.13
Example3 5 36.42+2.49 It can be seen from Table 3 that compared with mice in the control
group, the percentage of phagocytosis of chicken red blood cells by
peritoneal macrophages of the sample group is significantly different
(P<0.05).
The functional evaluation results show that the results of the above
experiments show that there are significant differences in the results of
the mouse serum hemolysin determination experiment, the
antibody-producing cell detection experiment, and the mouse peritoneal
macrophage phagocytosis of chicken red blood cells. According to the evaluation criteria, it can be considered that the sample group has the function of enhancing immunity.
4. The safety toxicology test of the composition
Samples: samples prepared in Examples 1 to 3.
Experimental animals: clean-grade Kunming mice; according to the
food intake of the experimental animals, the maximum dose is designed
to be 1Og/d, fed directly, and observe and record the situation.
Safety toxicology evaluation method: acute toxicity test (MTD
method) and genetic toxicity test are carried out on the composition. The
genetic toxicity test includes ames test, mouse bone marrow
polychromatic erythrocyte micronucleus test and mouse sperm
abnormality test.
After being fed with the highest dose, this product did not cause
abnormal changes in the overall health status, physiological and
biochemical functions, organ tissue morphology and other important
indicators. It belongs to the actual non-toxic category.
Genotoxicity test Ames test: The results of the three genotoxicity
tests of the mouse bone marrow polychromatic erythrocyte micronucleus
test and the mouse sperm abnormality test were negative, indicating that
this product has no mutagenic and teratogenic effects.
5. Sleep improvement test:
Samples: samples prepared in Examples 1 to 3.
Experimental animals: 40 clean ICR healthy mice, weighing 18-22g.
In this experiment, the animals were randomly divided into two
experimental groups: one group was carried out to extend the sleep time
of pentobarbital sodium, and the other group was subjected to barbital
sodium sleep latency experiment, with 5 animals in each group.
The sample prepared in Example 1 was used as the sample group.
According to Example 1, the composition was replaced with the same
amount of skimmed milk powder as the control group. According to the
"Technical Specifications for Health Food Inspection and Evaluation",
the experiment of extending the sleep time of pentobarbital sodium was
carried out and Barbital sodium sleep latency experiment. Feed once a
day for 30 days.
Table 6 Effects of samples on pentobarbital sodium-induced sleep time in
mice
project Number of sleeping animals (only) time/s(X s)
Control group 5 3012±504
Example 5 3752±612
Example2 5 3674±543
Example3 5 3826±534 Table 7 Effects of samples on pentobarbital sodium-induced sleep latency
in mice project Number of Sleep latency (X s) animals (only)
Control group 5 2531+542
Example 5 1845+337
Example2 5 1954+354
Example3 5 1876+341
The effect of the sample on the sleep time of mice induced by
pentobarbital sodium: the sleep time of animals in each group was
prolonged, and the difference between the sample group and the control
group was statistically significant (P<0.05), indicating that the sample can
prolong the pentobarbital sodium induction Sleep time of mice.
The effect of the sample on the sleep latency of mice induced by
barbital sodium: the latency of each group of animals was shortened, and
the difference between the sample group and the control group was
statistically significant (P<0.05), indicating that the sample can shorten
the barbital sodium induction The sleep latency of mice.
According to the judgment standard of "Technical Specification for
Health Food Inspection and Evaluation", it is judged that the sample has
the effect of improving sleep. The above embodiments are only used to illustrate the technical solutions of the present invention. Although the present invention has been described in detail with reference to preferred embodiments, those of ordinary skill in the art should understand that the technical solutions of the present invention can be modified or equivalently replaced. Without departing from the spirit and scope of the technical solution of the present invention, it should be covered in the scope of the claims of the present invention.
Claims (5)
1. A modified milk powder containing IgG, a-lactalbumin and
lactoferrin, characterized in that it is made from the following raw
materials in parts by mass: 383-408 parts of isolated whey protein powder
containing IgG, and isolated milk containing lactoferrin 37~42 parts of
albumin powder, 122~134 parts of whey protein powder containing
a-lactalbumin, 187~204 parts of anhydrous glucose, 164~176 parts of
whole milk powder, 48~52 parts of stachyose, 3.4~4.8 parts of isomerized
lactose, 0.7~0.9 parts of L-ascorbic acid, 0.1~0.3 parts of taurine.
2. The modified milk powder containing IgG, a-lactalbumin and
lactoferrin according to claim 1, wherein the IgG-containing isolated
whey protein powder contains 25% IgG by mass;
The lactoferrin-containing whey protein isolate powder contains 30%
by mass of lactoferrin;
The alpha-lactalbumin-containing whey protein powder contains 30%
by mass of alpha-lactalbumin.
3.The method for preparing a modulated milk powder containing
IgG, a-lactalbumin and lactoferrin according to any one of claims 1 to 2,
characterized in that it comprises the following steps:
S1. Feed anhydrous glucose, whole milk powder, stachyose,
isomerized lactose, L-ascorbic acid, and taurine in proportions and mix them uniformly to form mixed powder A;
S2. IgG-containing whey protein powder, lactoferrin-containing
whey protein powder, a-lactalbumin-containing whey protein powder and
mixed powder A with a mass of 25% to 42% are mixed uniformly, under
the environmental condition which are relative humidity is 30~35% and
the temperature is 20~23°C. The mixed powder B is obtained.
S3. Re-granulate the remaining mixed powder A and mixed powder
B. The method of re-granulation is that the mixed powder A and mixed
powder B are fed into a single-shaft roller press and pressed to form a
successfully combined mixed powder C. And uncombined mixed powder
A and mixed powder B;
S4. The output of step S3 enters the grinding device and the
vibrating screening device. The grinding device grinds the mixed powder
C containing blocky heterogeneity and homogenizes the mixed powder D
into the finished product. The mixed powder A and mixed powder B are
sifted out and recycled into the single-shaft roller press again.
4. The method for preparing a modulated milk powder containing
IgG, a-lactalbumin and lactoferrin according to claim 3, characterized in
that, in step S3, the remaining mixed powder A and mixed powder B are
fed separately. The feeding speed of mixed powder A is 1.4-2.3 times of
mixed powder B.
5. The method for preparing milk powder containing IgG, a-lactalbumin and lactoferrin according to claim 3, characterized in that, in step S3, the uniaxial roller press is provided with a heat conducting device, The temperature of the single-shaft roller press is 30-35°C, the relative humidity is 30~35%, and the external environment temperature of the single-shaft roller press is 20-25°C; the speed of the rollers of the single-shaft roller press is 30~60rpm.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2020102693A AU2020102693A4 (en) | 2020-10-13 | 2020-10-13 | Modulated milk powder with IgG, α-lactalbumin and lactoferrin and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2020102693A AU2020102693A4 (en) | 2020-10-13 | 2020-10-13 | Modulated milk powder with IgG, α-lactalbumin and lactoferrin and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2020102693A4 true AU2020102693A4 (en) | 2020-12-03 |
Family
ID=73551722
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020102693A Active AU2020102693A4 (en) | 2020-10-13 | 2020-10-13 | Modulated milk powder with IgG, α-lactalbumin and lactoferrin and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| AU (1) | AU2020102693A4 (en) |
-
2020
- 2020-10-13 AU AU2020102693A patent/AU2020102693A4/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2390269C2 (en) | Use of milk mix for babyfood with decreased protein content | |
| CN108812909B (en) | Complementary food nutritional supplement for improving monophagia or anorexia and preparation method thereof | |
| KR100509681B1 (en) | Food composition for stimulating growth comprising fraction isolated from mammalian colostrum or milk whey | |
| Jain et al. | Development of low cost nutritional beverage from whey | |
| EP4223137A1 (en) | Whey protein composition, and preparation method therefor and use thereof | |
| JPS6037933A (en) | Powdery food and production thereof | |
| TW201934016A (en) | Hydrolysat proteique de fabacees comme source proteique hypoallergenique dans des compositions alimentaires | |
| AU2020102693A4 (en) | Modulated milk powder with IgG, α-lactalbumin and lactoferrin and preparation method thereof | |
| EP2484226A1 (en) | Protein mixture of meat extract and collagen | |
| RU2270576C2 (en) | Biological method for production of food-grade preparation based on haem iron and food-grade preparation obtained thereby | |
| CN1419838A (en) | Total nutrient health protein powder | |
| NZ768834A (en) | Modulated milk powder with IgG, α-lactalbumin and lactoferrin and preparation method thereof | |
| CN102450330A (en) | Composite protein milk powder and production method thereof | |
| JP3029057B2 (en) | Milk composition for food allergy | |
| CN109938249B (en) | Rice protein composition | |
| JP3366769B2 (en) | Nutritional composition containing milt | |
| CN105249239A (en) | Nutritious compound rice noodles and preparation method thereof | |
| CN106538691A (en) | A kind of milk product | |
| EP3057450B1 (en) | Food composition | |
| JP3247786B2 (en) | Foods Highly Containing β-Casein | |
| EP3897213B1 (en) | Protein compositions with high isoelectric proteins | |
| US20240251808A1 (en) | Whey protein composition, and preparation method therefor and use thereof | |
| JPS6345792B2 (en) | ||
| KR100384115B1 (en) | the manufacturing method of food using extracted material in earthworm | |
| CN113545399A (en) | Dairy product and method for producing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGI | Letters patent sealed or granted (innovation patent) |